Becton Dickinson & Co (BDX) stock
BDXNYSESurgical & Medical Instruments & ApparatusFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 13/3021% above fair value
$216.47−1.56 (-0.72%)
Close on Nov 16, 2026Market cap $58.96BP/E 65.4Yield 1.92%
Becton Dickinson r&d expenses
Research and development expenses are spending on new products and technology.
Becton Dickinson's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.37B, up 23.9% year over year. For fiscal 2025 it was $1.27B, up 6.3% from the year before. Over ten years it grew 7.2% a year on average. The highest annual figure on record is $1.28B in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.27B | +6.3% |
| FY2024 | Sep 30, 2024 | $1.19B | -3.8% |
| FY2023 | Sep 30, 2023 | $1.24B | -1.5% |
| FY2022 | Sep 30, 2022 | $1.26B | -1.8% |
| FY2021 | Sep 30, 2021 | $1.28B | +23.1% |
| FY2020 | Sep 30, 2020 | $1.04B | -2.2% |
| FY2019 | Sep 30, 2019 | $1.06B | +5.8% |
| FY2018 | Sep 30, 2018 | $1.00B | +30.4% |
| FY2017 | Sep 30, 2017 | $770.00M | -7.0% |
| FY2016 | Sep 30, 2016 | $828.00M | +31.0% |
| FY2015 | Sep 30, 2015 | $632.00M | +14.9% |
| FY2014 | Sep 30, 2014 | $550.00M | +11.3% |
| FY2013 | Sep 30, 2013 | $494.00M | +4.7% |
| FY2012 | Sep 30, 2012 | $472.00M | +0.4% |
| FY2011 | Sep 30, 2011 | $470.00M | +11.2% |
| FY2010 | Sep 30, 2010 | $422.77M | +4.5% |
| FY2009 | Sep 30, 2009 | $404.57M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $258.00M | +12.2% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $249.00M | +7.3% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $306.00M | -10.8% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $559.00M | +85.1% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $230.00M | -23.1% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $232.00M | -22.4% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $343.00M | +18.3% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $302.00M | +7.5% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $299.00M | -2.3% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $299.00M | -11.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $290.00M | -7.3% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $281.00M | -6.3% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $306.00M | -2.9% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $337.00M | +3.1% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $313.00M | -0.3% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $300.00M | -18.5% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $315.00M | -4.5% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $327.00M | +3.2% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $314.00M | +7.9% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $368.00M | +52.1% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $330.00M | +26.0% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $317.00M | +20.1% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $291.00M | +7.8% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $242.00M | -10.4% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $262.00M | -7.1% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $264.00M | +4.8% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $270.00M | +4.7% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $270.00M | -2.5% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $282.00M | +1.8% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $252.00M | -2.7% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $258.00M | +35.1% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $277.00M | +28.2% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $277.00M | +48.9% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $259.00M | +38.5% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $191.00M | +4.9% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $216.00M | -14.6% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $186.00M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $187.00M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $182.00M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $253.00M | – |
See a number that looks wrong?